Cancer cells, particularly those with BRCA1 or BRCA2 mutations, often rely on PARP enzymes to repair their DNA and continue growing. Olaparib inhibits these PARP enzymes, causing the cancer cells to accumulate DNA damage and ultimately leading to their death. This mechanism is particularly effective in cells that are already compromised in their ability to repair DNA due to these genetic mutations.
